About CLINUVEL

Mrs Brenda Shanahan

BEc, BCom

Non-Executive Director

Mrs Shanahan has a longstanding background in finance in Australian and overseas’ economies and share markets and is a Fellow of the Institute of Directors. She is currently Chair of St Vincent's Medical Research Institute in Melbourne, a non-executive Director of DMP Asset Management, a non-executive Director of Challenger Limited (ASX:CGF) and a Director of the Kimberley Foundation of Australia. Mrs Shanahan is the former Chair of Challenger Listed Investments Ltd, the reporting entity for Challenger Kenedix Japan Trust (ASX:CKT), Challenger Infrastructure Fund (ASX:CIF), Challenger Diversified Property Group (ASX: CDI) and Challenger Wine Trust (ASX:CWT).

She is a former member of the Australian Stock Exchange and former executive director of a stockbroking firm, a fund management company and an actuarial company. Mrs Shanahan is well known in the business and financial community; her insights add significant value to the current Board and the company. Mrs Shanahan was Non-Executive Chair of the CLINUVEL Board from late 2007 until July 2010.

Latest Company Announcements

10 January 2018

Chair Letter to Shareholders

Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead.

Read More
21 December 2017

CLINUVEL Newsletter - December 2017

In the last communiqué of the calendar year, we take a breath and contemplate CLINUVEL’s status, a holding position for our teams over Christmas in the run up to a full 2018.

Read More
20 December 2017

Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England

CLINUVEL PHARMACEUTICALS LTD today announced that the first draft assessment from England’s National Institute for Health and Care Excellence (NICE) has been published,

Read More
07 December 2017

CLINUVEL Newsletter - December 2017

The CLINUVEL team is looking with much optimism and energy to the start of 2018.

Read More
05 December 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
05 December 2017

Appendix 3Z - Final Director’s Interest Notice

Final Director’s Interest Notice

Read More

Quick Links